More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.30B
EPS
-1.3
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-1.196857
Previous close
$18.57
Today's open
$18.53
Day's range
$17.81 - $18.70
52 week range
$17.81 - $94.90
show more
CEO
Raymond Stevens
Employees
281
Headquarters
South San Francisco, CA
Exchange
NASDAQ Global Market
Shares outstanding
71590355
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
Zacks Investment Research • Nov 13, 2026

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),demonstrating a ~6-day half-life and no serious adverse events; MAD clinical trial dosing underway, with topline data expected in 1H 2027 Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026expected to fund projected operations and key clinical milestones through 2028 SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio. “With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management,” said Raymond Stevens, Ph.D.
GlobeNewsWire • Nov 9, 2026

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
Zacks Investment Research • Nov 9, 2026

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will participate in the Jefferies Global Healthcare Conference being held November 16-19, 2026 in London, UK. Jefferies Global Healthcare Conference Date: Tuesday, November 17Format: Fireside chat and 1x1 meetingsTime: 12:00 PM GMTLocation: London, UK The live and archived webcasts will be accessible from the company's website at https://ir.structuretx.com/events-presentations/events and replays will be available for at least 90 days.
GlobeNewsWire • Nov 4, 2026

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m.
GlobeNewsWire • Oct 19, 2026

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Zacks Investment Research • Oct 12, 2026

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Zacks Investment Research • Sep 17, 2026

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 16, 2026

Structure Therapeutics: The Amylin Data Changes The Math
Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
Seeking Alpha • Sep 9, 2026

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
Seeking Alpha • Sep 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Structure Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.